105 related articles for article (PubMed ID: 26458465)
21. Clinical and molecular aspects of RAS related disorders.
Denayer E; de Ravel T; Legius E
J Med Genet; 2008 Nov; 45(11):695-703. PubMed ID: 18550698
[TBL] [Abstract][Full Text] [Related]
22. Mosaic RASopathies: A review of disorders caused by somatic pathogenic variants in the genes of the RAS/MAPK pathway.
Carli D; Resta N; Ferrero GB; Ruggieri M; Mussa A
Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):520-529. PubMed ID: 36461154
[TBL] [Abstract][Full Text] [Related]
23. Pediatric Myelodysplastic Syndrome With Germline RRAS Mutation: Expanding the Phenotype of RASopathies.
Catts DS; Mroske C; Clark RO; Hipp SJ; Berg JM; Hunter JM; Whiteway SL
J Pediatr Hematol Oncol; 2021 May; 43(4):e517-e520. PubMed ID: 32815881
[TBL] [Abstract][Full Text] [Related]
24. Integrated in silico MS-based phosphoproteomics and network enrichment analysis of RASopathy proteins.
Montero-Bullón JF; González-Velasco Ó; Isidoro-García M; Lacal J
Orphanet J Rare Dis; 2021 Jul; 16(1):303. PubMed ID: 34229750
[TBL] [Abstract][Full Text] [Related]
25. Down syndrome, RASopathies, and other rare syndromes.
Kratz CP; Izraeli S
Semin Hematol; 2017 Apr; 54(2):123-128. PubMed ID: 28637616
[TBL] [Abstract][Full Text] [Related]
26. [Prenatal diagnosis of Rasopathies in Ras/MAPK signaling pathway].
Zhang J; Zeng Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Nov; 37(11):1291-1295. PubMed ID: 33179243
[TBL] [Abstract][Full Text] [Related]
27. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
Tidyman WE; Rauen KA
Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
[TBL] [Abstract][Full Text] [Related]
28. The musculoskeletal phenotype of the RASopathies.
Stevenson DA; Yang FC
Am J Med Genet C Semin Med Genet; 2011 May; 157C(2):90-103. PubMed ID: 21495174
[TBL] [Abstract][Full Text] [Related]
29. Activation of the MAPK pathway (RASopathies) and partial growth hormone insensitivity.
Malaquias AC; Jorge AAL
Mol Cell Endocrinol; 2021 Jan; 519():111040. PubMed ID: 33011209
[TBL] [Abstract][Full Text] [Related]
30. Divergent effects of intrinsically active MEK variants on developmental Ras signaling.
Goyal Y; Jindal GA; Pelliccia JL; Yamaya K; Yeung E; Futran AS; Burdine RD; Schüpbach T; Shvartsman SY
Nat Genet; 2017 Mar; 49(3):465-469. PubMed ID: 28166211
[TBL] [Abstract][Full Text] [Related]
31. Peripheral muscle weakness in RASopathies.
Stevenson DA; Allen S; Tidyman WE; Carey JC; Viskochil DH; Stevens A; Hanson H; Sheng X; Thompson BA; Okumura MJ; Reinker K; Johnson B; Rauen KA
Muscle Nerve; 2012 Sep; 46(3):394-9. PubMed ID: 22907230
[TBL] [Abstract][Full Text] [Related]
32. RASopathies: Evolving Concepts in Pathogenetics, Clinical Features, and Management.
Padhiyar J; Mahajan R; Panda M
Indian Dermatol Online J; 2024; 15(3):392-404. PubMed ID: 38845651
[TBL] [Abstract][Full Text] [Related]
33. Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations.
Kiel C; Serrano L
Mol Syst Biol; 2014 May; 10(5):727. PubMed ID: 24803665
[TBL] [Abstract][Full Text] [Related]
34. Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway.
Jorge AA; Malaquias AC; Arnhold IJ; Mendonca BB
Horm Res; 2009; 71(4):185-93. PubMed ID: 19258709
[TBL] [Abstract][Full Text] [Related]
35. Deregulated Ras signaling in developmental disorders: new tricks for an old dog.
Schubbert S; Bollag G; Shannon K
Curr Opin Genet Dev; 2007 Feb; 17(1):15-22. PubMed ID: 17208427
[TBL] [Abstract][Full Text] [Related]
36. Understanding intellectual disability through RASopathies.
San Martín A; Pagani MR
J Physiol Paris; 2014; 108(4-6):232-9. PubMed ID: 24859216
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of RAS activation due to a homozygous ezrin variant in patients with profound intellectual disability.
Riecken LB; Tawamie H; Dornblut C; Buchert R; Ismayel A; Schulz A; Schumacher J; Sticht H; Pohl KJ; Cui Y; Reis A; Morrison H; Abou Jamra R
Hum Mutat; 2015 Feb; 36(2):270-8. PubMed ID: 25504542
[TBL] [Abstract][Full Text] [Related]
38. [Molecular genetic diagnostics in syndromes associated with the RAS/MAPK signalling pathway].
Molven A; Søvik O; von der Lippe C; Steine SJ; Njølstad PR; Houge G; Prescott TE
Tidsskr Nor Laegeforen; 2009 Nov; 129(22):2358-61. PubMed ID: 19935936
[TBL] [Abstract][Full Text] [Related]
39. Human HOX gene disorders.
Quinonez SC; Innis JW
Mol Genet Metab; 2014 Jan; 111(1):4-15. PubMed ID: 24239177
[TBL] [Abstract][Full Text] [Related]
40. Skeletal muscle pathology in Costello and cardio-facio-cutaneous syndromes: developmental consequences of germline Ras/MAPK activation on myogenesis.
Tidyman WE; Lee HS; Rauen KA
Am J Med Genet C Semin Med Genet; 2011 May; 157C(2):104-14. PubMed ID: 21495178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
